{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:56Z","timestamp":1786979936405,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00277-020-03942-6","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T03:02:56Z","timestamp":1580871776000},"page":"819-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"99","author":[{"given":"Do Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-seop","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-7031","authenticated-orcid":false,"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"issue":"6","key":"3942_CR1","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.3324\/haematol.2014.119214","volume":"100","author":"KB Smeland","year":"2015","unstructured":"Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli U-M, Falk RS, Fluge \u00d8, Foss\u00e5 A, Kolstad A, Loge JH, Maisenh\u00f6lder M, Kval\u00f8y S, Holte H (2015) Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. Haematologica 100(6):e240\u2013e243. https:\/\/doi.org\/10.3324\/haematol.2014.119214","journal-title":"Haematologica"},{"issue":"9","key":"3942_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1634\/theoncologist.2009-0162","volume":"14","author":"AJ Moskowitz","year":"2009","unstructured":"Moskowitz AJ, Moskowitz CH (2009) Controversies in the treatment of lymphoma with autologous transplantation. Oncologist 14(9):921\u2013929. https:\/\/doi.org\/10.1634\/theoncologist.2009-0162","journal-title":"Oncologist"},{"issue":"18","key":"3942_CR3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","volume":"369","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369(18):1681\u20131690. https:\/\/doi.org\/10.1056\/NEJMoa1301077","journal-title":"N Engl J Med"},{"issue":"33","key":"3942_CR4","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/jco.2016.67.2980","volume":"34","author":"S Cortelazzo","year":"2016","unstructured":"Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mule A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A (2016) Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol 34(33):4015\u20134022. https:\/\/doi.org\/10.1200\/jco.2016.67.2980","journal-title":"J Clin Oncol"},{"issue":"2","key":"3942_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.1996.14.2.586","volume":"14","author":"R Pettengell","year":"1996","unstructured":"Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D (1996) Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 14(2):586\u2013592. https:\/\/doi.org\/10.1200\/jco.1996.14.2.586","journal-title":"J Clin Oncol"},{"issue":"13","key":"3942_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa031770","volume":"350","author":"N Milpied","year":"2004","unstructured":"Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350(13):1287\u20131295. https:\/\/doi.org\/10.1056\/NEJMoa031770","journal-title":"N Engl J Med"},{"issue":"3","key":"3942_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/jco.1995.13.3.588","volume":"13","author":"W Mills","year":"1995","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13(3):588\u2013595. https:\/\/doi.org\/10.1200\/jco.1995.13.3.588","journal-title":"J Clin Oncol"},{"issue":"7","key":"3942_CR8","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","volume":"77","author":"T Philip","year":"1991","unstructured":"Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J et al (1991) Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77(7):1587\u20131592","journal-title":"Blood"},{"issue":"7","key":"3942_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbmt.2006.03.016","volume":"12","author":"C Aggarwal","year":"2006","unstructured":"Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, Nance AG, Tilden AB, Carabasi MH (2006) Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 12(7):770\u2013777. https:\/\/doi.org\/10.1016\/j.bbmt.2006.03.016","journal-title":"Biol Blood Marrow Transplant"},{"key":"3942_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/sj.bmt.1702433","volume":"25","author":"EA Copelan","year":"2000","unstructured":"Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, Kalaycio M, Bechtel TP, Scholl MD, Elder PJ, Ezzone SA, O'Donnell LC, Tighe MB, Risley GL, Young DC, Bolwell BJ (2000) Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 25:1243\u20131248. https:\/\/doi.org\/10.1038\/sj.bmt.1702433","journal-title":"Bone Marrow Transplant"},{"key":"3942_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/bmt.2008.429","volume":"44","author":"MP Escal\u00f3n","year":"2009","unstructured":"Escal\u00f3n MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M, Byrnes JJ, Fernandez HF (2009) Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 44:89\u201396. https:\/\/doi.org\/10.1038\/bmt.2008.429","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3942_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00277-001-0413-8","volume":"81","author":"M H\u00e4nel","year":"2002","unstructured":"H\u00e4nel M, Kr\u00f6ger N, Sonnenberg S, Bornh\u00e4user M, Kr\u00fcger W, Kroschinsky F, H\u00e4nel A, Metzner B, Birkmann J, Schmid B, Hoffknecht M, Fiedler F, Ehninger G, Zander A (2002) Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 81(2):96\u2013102. https:\/\/doi.org\/10.1007\/s00277-001-0413-8","journal-title":"Ann Hematol"},{"key":"3942_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/sj.bmt.1705841","volume":"40","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH (2007) Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu\/Cy\/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 40:919\u2013924. https:\/\/doi.org\/10.1038\/sj.bmt.1705841","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3942_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","volume":"35","author":"JE Kim","year":"2011","unstructured":"Kim JE, Lee DH, Yoo C, Kim S, Kim S-W, Lee J-S, Park CJ, Huh J, Suh C (2011) BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 35(2):183\u2013187. https:\/\/doi.org\/10.1016\/j.leukres.2010.07.016","journal-title":"Leuk Res"},{"key":"3942_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/sj.bmt.1701033","volume":"21","author":"N Kr\u00f6ger","year":"1998","unstructured":"Kr\u00f6ger N, Hoffknecht M, Dreger P, Kr\u00fcger W, Zeller W, Kr\u00fcll A, Stockschl\u00e4der M, Bittner S, Weh HJ, Zander AR (1998) Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 21:55\u201357. https:\/\/doi.org\/10.1038\/sj.bmt.1701033","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3942_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbmt.2004.05.010","volume":"10","author":"CB Williams","year":"2004","unstructured":"Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP (2004) Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 10(9):614\u2013623. https:\/\/doi.org\/10.1016\/j.bbmt.2004.05.010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"3942_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.bbmt.2012.02.006","volume":"18","author":"H Zhang","year":"2012","unstructured":"Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z, Flowers CR, Waller EK (2012) Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 18(8):1287\u20131294. https:\/\/doi.org\/10.1016\/j.bbmt.2012.02.006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3942_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS (2009) Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(5):523\u2013536. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.489","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3942_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.Ccr-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309\u2013317. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1061","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3942_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00280-015-2727-6","volume":"75","author":"M Darwish","year":"2015","unstructured":"Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP (2015) Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol 75(6):1143\u20131154. https:\/\/doi.org\/10.1007\/s00280-015-2727-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3942_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/jco.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586. https:\/\/doi.org\/10.1200\/jco.2006.09.2403","journal-title":"J Clin Oncol"},{"issue":"9323","key":"3942_CR22","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/s0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359(9323):2065\u20132071. https:\/\/doi.org\/10.1016\/s0140-6736(02)08938-9","journal-title":"Lancet"},{"issue":"24","key":"3942_CR23","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/nejm198706113162401","volume":"316","author":"T Philip","year":"1987","unstructured":"Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M et al (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316(24):1493\u20131498. https:\/\/doi.org\/10.1056\/nejm198706113162401","journal-title":"N Engl J Med"},{"issue":"23","key":"3942_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/nejm199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540\u20131545. https:\/\/doi.org\/10.1056\/nejm199512073332305","journal-title":"N Engl J Med"},{"issue":"4","key":"3942_CR25","first-page":"549","volume":"15","author":"K van Besien","year":"1995","unstructured":"van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I et al (1995) High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 15(4):549\u2013555","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3942_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/blood.V73.1.340.340","volume":"73","author":"JG Gribben","year":"1989","unstructured":"Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH (1989) Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73(1):340\u2013344","journal-title":"Blood"},{"issue":"1","key":"3942_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","volume":"87","author":"JC Jo","year":"2008","unstructured":"Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C (2008) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 87(1):43\u201348. https:\/\/doi.org\/10.1007\/s00277-007-0360-0","journal-title":"Ann Hematol"},{"issue":"4","key":"3942_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.bmt.1702795","volume":"27","author":"A Salar","year":"2001","unstructured":"Salar A, Sierra J, Gandarillas M, Caballero MD, Marin J, Lahuerta JJ, Garcia-Conde J, Arranz R, Leon A, Zuazu J, Garcia-Larana J, Lopez-Guillermo A, Sanz MA, Granena A, Garcia JC, Conde E (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 27(4):405\u2013412. https:\/\/doi.org\/10.1038\/sj.bmt.1702795","journal-title":"Bone Marrow Transplant"},{"issue":"3\u20134","key":"3942_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/10428199509056831","volume":"17","author":"W Mills","year":"1995","unstructured":"Mills W, Strang J, Goldstone AH, Linch DC (1995) Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymphoma 17(3\u20134):263\u2013270. https:\/\/doi.org\/10.3109\/10428199509056831","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"3942_CR30","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","volume":"105","author":"S Bhatia","year":"2005","unstructured":"Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave PB, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study. Blood 105(11):4215\u20134222. https:\/\/doi.org\/10.1182\/blood-2005-01-0035","journal-title":"Blood"},{"issue":"11","key":"3942_CR31","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1080\/10428194.2016.1185785","volume":"57","author":"A Isidori","year":"2016","unstructured":"Isidori A, Christofides A, Visani G (2016) Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 57(11):2499\u20132509. https:\/\/doi.org\/10.1080\/10428194.2016.1185785","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"3942_CR32","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood 118(12):3419\u20133425. https:\/\/doi.org\/10.1182\/blood-2011-04-351924","journal-title":"Blood"},{"issue":"1","key":"3942_CR33","first-page":"47","volume":"5","author":"EA Copelan","year":"1990","unstructured":"Copelan EA, Kapoor N, Gibbins B, Tutschka PJ (1990) Allogeneic marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 5(1):47\u201350","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3942_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2141.2009.07940.x","volume":"148","author":"RM Dean","year":"2010","unstructured":"Dean RM, Pohlman B, Sweetenham JW, Sobecks RM, Kalaycio ME, Smith SD, Copelan EA, Andresen S, Rybicki LA, Curtis J, Bolwell BJ (2010) Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 148(2):226\u2013234. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07940.x","journal-title":"Br J Haematol"},{"issue":"3","key":"3942_CR35","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1097\/MPH.0b013e3181fd6c79","volume":"33","author":"M Andion","year":"2011","unstructured":"Andion M, Molina B, Gonzalez-Vicent M, Alonso L, Hernandez C, Lassaletta A, Lopez-Ibor B, Villa M, Diaz MA (2011) High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol 33(3):e89\u2013e91. https:\/\/doi.org\/10.1097\/MPH.0b013e3181fd6c79","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"3942_CR36","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3109\/10428194.2014.882504","volume":"55","author":"HJ Shin","year":"2014","unstructured":"Shin HJ, Lee WS, Lee HS, Kim H, Lee GW, Song MK, Kim JS, Yhim HY, Chung JS (2014) Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 55(11):2490\u20132496. https:\/\/doi.org\/10.3109\/10428194.2014.882504","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"3942_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","volume":"34","author":"EH Wang","year":"2004","unstructured":"Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34(7):581\u2013587. https:\/\/doi.org\/10.1038\/sj.bmt.1704637","journal-title":"Bone Marrow Transplant"},{"key":"3942_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/2193-1801-2-489","volume":"2","author":"A Sharma","year":"2013","unstructured":"Sharma A, Kayal S, Iqbal S, Malik PS, Raina V (2013) Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. SpringerPlus 2:489. https:\/\/doi.org\/10.1186\/2193-1801-2-489","journal-title":"SpringerPlus"},{"issue":"2","key":"3942_CR39","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1002\/ajh.25340","volume":"94","author":"M Lucijanic","year":"2019","unstructured":"Lucijanic M, Prka Z, Jaksic O, Mitrovic Z, Vrkljan A, Pejsa V (2019) Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality. Am J Hematol 94(2):E42\u2013e43. https:\/\/doi.org\/10.1002\/ajh.25340","journal-title":"Am J Hematol"},{"key":"3942_CR40","doi-asserted-by":"publisher","unstructured":"Redondo AM, Valcarcel D, Gonzalez-Rodriguez AP, Suarez-Lledo M, Bello JL, Canales M, Gayoso J, Colorado M, Jarque I, Del Campo R, Arranz R, Terol MJ, Rifon JJ, Rodriguez MJ, Ramirez MJ, Castro N, Sanchez A, Lopez-Jimenez J, Montes-Moreno S, Briones J, Lopez A, Palomera L, Lopez-Guillermo A, Caballero D, Martin A (2018) Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.15713","DOI":"10.1111\/bjh.15713"},{"issue":"6","key":"3942_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","volume":"93","author":"SP Chantepie","year":"2018","unstructured":"Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursiere E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G (2018) Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol 93(6):729\u2013735. https:\/\/doi.org\/10.1002\/ajh.25077","journal-title":"Am J Hematol"},{"issue":"12","key":"3942_CR42","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/s1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13(12):1250\u20131259. https:\/\/doi.org\/10.1016\/s1470-2045(12)70481-3","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03942-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-03942-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03942-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T19:15:03Z","timestamp":1612379703000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-03942-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["3942"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-03942-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}